PTEN regulatory functions in tumor suppression and cell biology

Medical Science Monitor

Volumn 10, Issue 10, 2004, Pages

  Chu, Eric C ^a   Tarnawski, Andrzej S ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA LONG BEACH HEALTHCARE SYSTEM   (United States)

^c NONE   (United States)

Author keywords

PTEN; Review; Tumor suppressor

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATASE; PHOSPHATIDATE PHOSPHATASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHOPROTEIN PHOSPHATASE; PROTEIN P53; TUMOR SUPPRESSOR PROTEIN;

ADVANCED CANCER; ALLELE; ANGIOGENESIS; APOPTOSIS; CANCER CELL CULTURE; CANCER INHIBITION; CELL FUNCTION; CELL MIGRATION; CYTOLOGY; ENZYME ACTIVITY; GENE DELETION; HEMATOLOGIC MALIGNANCY; HUMAN; METASTASIS; MITOSIS INHIBITION; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; TUMOR GROWTH;

GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASMS; PHOSPHORIC MONOESTER HYDROLASES; PTEN PHOSPHOHYDROLASE; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEINS;

EID: 7044249212     PISSN: 12341010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (101)

1. Li J, Yen C, Liaw D, Podsypanina K et al: PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science, 1997; 275: 1943-47
2. Steck PA, Pershouse MA, Jasser SA et al: Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet, 1997; 15: 356-62
3. Li DM, Sun H: TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta. Cancer Res, 1997; 57: 2124-29
4. Haynie DT, Ponting CP: The N-terminal domains of tensin and auxilin are phosphatase homologues. Protein Sci, 1996; 5: 2643-46
5. Cantley LC, Neel BG: New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinasc/AKT pathway. Proc Natl Acad Sci USA, 1999; 96: 4240-45
6. Lee JO, Yang H, Georgescu MM et al: Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association. Cell. 1999; 99: 323-34
7. Tsugawa K, Jones MK, Sugimachi K et al: Biological role of phosphatase PTEN in cancer and tissue injury healing. Front Biosci, 2002; 7: e245-51
8. Wu X, Hepner K, Castelino-Prabhu S et al: Evidence for regulation of the PTEN tumor suppressor by a membrane-localized multi-PDZ domain containing scaffold protein MAGI-2. Proc Natl Acad Sci USA, 2000; 97: 4233-38
9. Wu Y, Dowbenko D, Spencer S et al: Interaction of the tumor suppressor PTEN/MMAC with a PDZ domain of MAGI3, a novel membrane-associated guanylate kinase. J Biol Chem, 2000; 275: 21477-85
10. Lee JO, Yang H, Georgescu MM et al: Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association. Cell, 1999; 99: 323-34
11. Wang SI, Puc J, Li J et al: Somatic mutations of PTEN in glioblastoma multiforme. Cancer Res, 1997; 57: 4183-86
12. Rasheed BK, Stenzel TT, McLendon RE et al: PTEN gene mutations are seen in high-grade but not in low-grade gliomas. Cancer Res. 1997; 57: 4187-90
13. Liu W, James CD, Frederick L et al: PTEN/MMAC1 mutations and EGFR amplification in glioblastomas. Cancer Res, 1997; 57: 5254-57
14. Bostrom J, Cobbers JM, Wolter M et al: Mutation of the PTEN (MMAC1) tumor suppressor gene in a subset of glioblastomas but not in meningiomas with loss of chromosome arm 10q. Cancer Res, 1998; 58: 29-33
15. Duerr EM, Rollbrocker B, Hayashi Y et al: PTEN mutations in gliomas and glioneuronal tumors. Oncogene, 1998; 16: 2259-64
16. Cairns P, Okami K, Halachmi S et al: Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res, 1997; 57: 4997-5000
17. Wang SI, Parsons R, Ittmann M: Homozygous deletion of the PTEN tumor suppressor gene in a subset of prostate adenocarcinomas. Clin Cancer Res, 1998; 4: 811-15
18. Feilotter HE, Nagai MA, Boag AH et al: Analysis of PTEN and the 10q23 region in primary prostate carcinomas. Oncogene, 1998; 16: 1743-48
19. Pesche S, Latil A, Muzcau F et al: PTEN/MMAC1/TEP1 involvement in primary prostate cancers. Oncogene, 1998; 16: 2879-83
20. Ali IU, Schriml LM, Dean M: Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity. J Natl Cancer Inst, 1999; 91: 1922-32
21. Tashiro H, Blazes MS, Wu R et al: Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res, 1997; 57: 3935-40
22. Kong D, Suzuki A, Zou TT et al: PTEN1 is frequently mutated in primary endometrial carcinomas. Nat Genet, 1997; 17: 143-44
23. Risinger JI, Haves AK, Berchuck A, Barrett JC: PTEN/MMAC1 mutations in endometrial cancers. Cancer Res, 1997; 57: 4736-38
24. Mutter GL, Lin MC, Fitzgerald JT et al: Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst, 2000; 92: 924-30
25. Teng DH, Hu R, Lin H et al: MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines. Cancer Res, 1997; 57: 5221-25
26. Reifenberger J, Wolter M, Bostrom J et al: Allelic losses on chromosome arm 10q and mutation of the PTEN (MMAC1) tumour suppressor gene in primary and metastatic malignant melanomas. Virchows Arch, 2000; 436: 487-93
27. Pollock PM, Walker GJ, Glendening JM et al: PTEN inactivation is rare in melanoma tumours but occurs frequently in melanoma cell lines. Melanoma Res, 2002; 12: 565-75
28. Rhei E, Kang L, Bogomolniy F et al: Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in primary breast carcinomas. Cancer Res, 1997; 57: 3657-59
29. Chen ST, Yu SY, Tsai M et al: Mutation analysis of the putative tumor suppression gene PTEN/MMAC1 in sporadic breast cancer. Breast Cancer Res Treat, 1999; 55: 85-89
30. Ueda K, Nishijima M, Inui H et al: Infrequent mutations in the PTEN/MMAC1 gene among primary breast cancers. Jpn J Cancer Res, 1998; 89: 17-21
31. Dahia PL, Marsh DJ, Zheng Z et al: Somatic deletions and mutations in the Cowden disease gene, PTEN, in sporadic thyroid tumors. Cancer Res, 1997; 57: 4710-13
32. Halachmi N, Halachmi S, Evron E et al: Somatic mutations of the PTEN tumor suppressor gene in sporadic follicular thyroid tumors. Genes Chromosomes Cancer, 1998; 23: 239-43
33. Hsieh MC, Lin SF, Shin SJ et al: Mutation analysis of PTEN/MMAC 1 in sporadic thyroid tumors. Kaohsiung J Med Sci, 2000; 16: 9-12
34. Frisk T, Foukakis T, Dwight T et al: Silencing of the PTEN tumor-suppressor gene in anaplastic thyroid cancer. Genes Chromosomes Cancer, 2002; 35: 74-80
35. Okami K, Wu L, Riggins G et al: Analysis of PTEN/MMAC1 alterations in aerodigestive tract tumors. Cancer Res, 1998; 58: 509-11
36. Shao X, Tandon R, Samara G et al: Mutational analysis of the PTEN gene in head and neck squamous cell carcinoma. Int J Cancer, 1998; 77: 684-88
37. Alimov A, Li C, Gizatullin R et al: Somatic mutation and homozygous deletion of PTEN/MMAC1 gene of 10q23 in renal cell carcinoma. Anticancer Res, 1999; 19: 3841-46
38. Kohno T, Takahashi M, Manda R, Yokota J: Inactivation of the PTEN/MMAC1/TEP1 gene in human lung cancers. Genes Chromosomes Cancer, 1998; 22: 152-56
39. Petersen S, Rudolf J, Bockmuhl U et al: Distinct regions of allelic imbalance on chromosome 10q22-q26 in squamous cell carcinomas of the lung. Oncogene, 1998; 17: 449-54
40. Yokomizo A, Tindall DJ, Drabkin H et al: PTEN/MMAC1 mutations identified in small cell, but not in non-small cell lung cancers. Oncogene, 1998; 17: 475-79
41. Forgacs E, Biesterveld EJ, Sekido Y et al: Mutation analysis of the PTEN/MMAC1 gene in lung cancer. Oncogene, 1998; 17: 1557-65
42. Nakahara Y, Nagai H, Kinoshita T et al: Mutational analysis of the PTEN/MMAC1 gene in non-Hodgkin's lymphoma. Leukemia, 1998; 12: 1277-80
43. Gronbaek K, Zeuthen J, Guldberg P et al: Alterations of the MMAC1/PTEN gene in lymphoid malignancies. Blood, 1998; 91: 4388-90
44. Sakai A, Thieblemont C, Wellmann A et al: PTEN gene alterations in lymphoid neoplasms. Blood, 1998; 92: 3410-15
45. Butler MP, Wang SI, Chaganti RS et al: Analysis of PTEN mutations and deletions in B-cell non-Hodgkin's lymphomas. Genes Chromosomes Cancer, 1999; 24: 322-27
46. Kawamura N, Nagai H, Bando K et al: PTEN/MMAC1 mutations in hepatocellular carcinomas: somatic inactivation of both alleles in tumors. Jpn J Cancer Res, 1999; 90: 413-18
47. Obata K, Morland SJ, Watson RH et al: Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors. Cancer Res, 1998; 58: 2095-97
48. Yokomizo A, Tindall DJ, Hartmann L et al: Mutation analysis of the putative tumor suppressor PTEN/MMAC1 in human ovarian cancer. Int J Oncol, 1998; 13: 101-15
49. Saito M, Okamoto A, Kohno T et al: Allelic imbalance and mutations of the PTEN gene in ovarian cancer. Int J Cancer, 2000; 85: 160-65
50. Marsh DJ, Coulon V, Lunetta KL et al: Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation. Hum Mol Genet, 1998; 7: 507-15
51. Zhou X, Hampel H, Thiele H et al: Association of germline mutation in the PTEN tumour suppressor gene and Proteus and Proteus-like syndromes. Lancet, 2001; 358: 210-11
52. Myers MP, Stolarov JP, Eng C et al: P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase. Proc Natl Acad Sci USA, 1997; 94: 9052-57
53. Maehama T, Dixon JE: The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem, 1998; 273: 13375-78
54. Stambolic V, Suzuki A, de la Pompa JL et al: Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell, 1998; 95: 29-39
55. Sun H, Lesche R, Li DM et al: PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5,-trisphosphate and Akt/protein kinase B signaling pathway. Proc Natl Acad Sci USA, 1999; 96: 6199-204
56. Wu X, Senechal K, Neshat MS et al: The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. Proc Natl Acad Sci USA, 1998; 95: 15587-91
57. Datta SR, Brunet A, Greenberg ME: Cellular survival: a play in three Akts. Genes Dev, 1999; 13: 2905-27
58. Di Cristofano A, Pandolfi PP: The multiple roles of PTEN in tumor suppression. Cell, 2000; 100: 387-90
59. Romashkova JA, Makarov SS: NF-kappaB is a target of AKT in anti-apoptolic PDGF signalling. Nature, 1999; 401: 86-90
60. Mayo LD, Donner DB: A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci USA, 2001; 98: 11598-603
61. Cross DA, Alessi DR, Cohen P et al: Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature, 1995; 378: 785-89
62. Weng LP, Brown JL, Eng C: PTEN coordinates G(1) arrest by down-regulating cyclin D1 via its protein phosphatase activity and up-regulating p27 via its lipid phosphatase activity in a breast cancer model. Hum Mol Genet, 2001; 10: 599-604
63. Vivanco I, Sawyers CL: The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer, 2002; 2: 489-501
64. Furnari FB, Lin H, Huang HS, Cavenee WK: Growth suppression of glioma cells by PTEN requires a functional phosphatase catalytic domain. Proc Natl Acad Sci USA, 1997; 94: 12479-84
65. Myers MP, Pass I, Batty IH et al: The lipid phosphatase activity of PTEN is critical for its tumor supressor function. Proc Natl Acad Sci USA, 1998; 95: 13513-18
66. Robertson GP, Furnari FB, Miele ME et al: In vitro loss of heterozygosity targets the PTEN/MMAC1 gene in melanoma. Proc Natl Acad Sci USA, 1998; 95: 9418-23
67. Li DM, Sun H: PTEN/MMAC1/TEP1 suppresses the tumorigenicity and induces G1 cell cycle arrest in human glioblastoma cells. Proc Natl Acad Sci USA, 1998; 95: 15406-11
68. Di Cristofano A, Pesce B, Cordon-Cardo C, Pandolfi PP: Pten is essential for embryonic development and tumour suppression. Nat Genet, 1998; 19: 348-55
69. Suzuki A, de la Pompa JL, Stambolic V et al: High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. Curr Biol, 1998; 8: 1169-78
70. Podsypanina K, Ellenson LH, Nemes A et al: Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci USA, 1999; 96: 1563-68
71. Stambolic V, Tsao MS, Macpherson D et al: High incidence of breast and endometrial neoplasia resembling human Cowden syndrome in pten+/-mice. Cancer Res, 2000; 60: 3605-11
72. Kwabi-Addo B, Giri D, Schmidt K et al: Haploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression. Proc Natl Acad Sci USA, 2001; 98: 11563-68
73. Trotman LC, Niki M, Dotan ZA et al: Pten dose dictates cancer progression in the prostate. PLoS Biol, 2003; 1: E59 (385-96)
74. Furnari FB, Huang HJ, Cavenee WK: The phosphoinositol phosphatase activity of PTEN mediates a serum-sensitive G1 growth arrest in glioma cells. Cancer Res, 1998; 58: 5002-8
75. Myers MP, Pass I, Batty IH, Van der Kaay J et al: The lipid phosphatase activity of PTEN is critical for its tumor supressor function. Proc Natl Acad Sci USA, 1998; 95: 13513-18
76. Mahimainathan L, Choudhury GG: Inactivation of platelet-derived growth factor receptor by the tumor suppressor PTEN provides a novel mechanism of action of the phosphatase. J Biol Chem, 2004; 279: 15258-68
77. Tamura M, Gu J, Matsumoto K et al: Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. Science, 1998; 280: 1614-17
78. Tamura M, Gu J, Danen EH et al: PTEN interactions with focal adhesion kinase and suppression of the extracellular matrix-dependent phosphatidylinositol 3-kinase/Akt cell survival pathway. J Biol Chem, 1999; 274: 20693-703
79. Maier D, Jones G, Li X et al: The PTEN lipid phosphatase domain is not required to inhibit invasion of glioma cells. Cancer Res, 1999; 59: 5479-82
80. Gu J, Tamura M, Pankov R et al: She and FAK differentially regulate cell motility and directionality modulated by PTEN. J Cell Biol, 1999; 146: 389-403
81. Yart A, Laffargue M, Mayeux P et al: A critical role for phosphoinositide 3-kinase upstream of Gab1 and SHP2 in the activation of ras and mitogen-activated protein kinases by epidermal growth factor. J Biol Chem, 2001; 276: 8856-64
82. Ong SH, Hadari YR, Gotoh N et al: Stimulation of phosphatidylinositol 3-kinase by fibroblast growth factor receptors is mediated by coordinated recruitment of multiple docking proteins. Proc Natl Acad Sci USA, 2001;98:6074-79
83. Weng LP, Smith WM, Brown JL, Eng C: PTEN inhibits insulin-stimulated MEK/MAPK activation and cell growth by blocking IRS-1 phosphorylation and IRS-1/Grb-2/Sos complex formation in a breast cancer model. Hum Mol Genet. 2001; 10: 605-16
84. Zundel W, Schindler C, Haas-Kogan D et al: Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev, 2000; 14: 391-96
85. Gomez-Manzano C, Fueyo J, Jiang H et al: Mechanisms underlying PTEN regulation of vascular endothelial growth factor and angiogenesis. Ann Neurol, 2003; 53: 109-17
86. Huang J, Kontos CD: PTEN modulates vascular endothelial growth factor-mediated signaling and angiogenic effects. J Biol Chem, 2002; 277: 10760-66
87. Abe T, Terada K, Wakimoto H et al: PTEN decreases in vivo vascularization of experimental gliomas in spite of proangiogenic stimuli. Cancer Res, 2003; 63: 2300-5
88. Gil EB, Malone Link E et al: Regulation of the insulin-like developmental pathway of Caenorhabditis elegans by a homolog of the PTEN tumor suppressor gene. Proc Natl Acad Sci USA, 1999; 96: 2925-30
89. Bringold F, Serrano M: Tumor suppressors and oncogenes in cellular senescence. Exp Gerontol. 2000; 35: 317-29
90. Vazquez F, Ramaswamy S, Nakamura N, Sellers WR: Phosphorylation of the PTEN tail regulates protein stability and function. Mol Cell Biol, 2000; 20: 5010-18
91. Vazquez F, Grossman SR, Takahashi Y et al: Phosphorylation of the PTEN tail acts as an inhibitory switch by preventing its recruitment into a protein complex. J Biol Chem, 2001; 276: 48627-30
92. Torres J, Pulido R: The tumor suppressor PTEN is phosphorylated by the protein kinase CK2 at its C terminus. Implications for PTEN stability to proteasome-mediated degradation. J Biol Chem, 2001; 276: 993-98
93. Torres J, Rodriguez J, Myers MP et al: Phosphorylation-regulated cleavage of the tumor suppressor PTEN by caspase-3: implications for the control of protein stability and PTEN-protein interactions. J Biol Chem, 2003; 278: 30652-60
94. Patel L, Pass I, Coxon P et al: Tumor suppressor and anti-inflammatory actions of PPARgamma agonists are mediated via upregulation of PTEN. Curr Biol, 2001; 11: 764-68
95. Stambolic V, MacPherson D, Sas D et al: Regulation of PTEN transcription by p53. Mol Cell, 2001; 8: 317-25
96. Virolle T, Adamson ED, Baron V et al: The Egr-1 transcription factor directly activates PTEN during irradiation-induced signalling. Nat Cell Biol, 2001; 3: 1124-28
97. Moorehead RA, Hojilla CV, De Belle I et al: Insulin-like growth factor-II regulates PTEN expression in the mammary gland. J Biol Chem, 2003; 278: 50422-27
98. Chu EC, Chai J, Tarnawski AS: NSAIDs activate PTEN and other phosphatases in human colon cancer cells: novel mechanism for chemopreventive action of NSAIDs. Biochem Biophys Res Commun, 2004; 320: 875-79
99. Guzeloglu-Kayisli O, Kayisli UA, Al-Rejjal R et al: Regulation of PTEN (phosphatase and tensin homolog deleted on chromosome 10) expression by estradiol and progesterone in human endometrium. J Clin Endocrinol Metab, 2003; 88: 5017-26
100. Vasudevan KM, Gurumurthy S, Rangnekar VM: Suppression of PTEN expression by NF-kappa B prevents apoptosis. Mol Cell Biol, 2004; 24: 1007-21
101. Kim S, Domon-Dell C, Kang J et al: Down-regulation of the tumor suppressor PTEN by the tumor necrosis factor-alpha/nuclear factor-kappaB (NF-kappaB)-inducing kinase/NF-kappaB pathway is linked to a default IkappaB-alpha autoregulatory loop. J Biol Chem, 2004; 279: 4285-91